New Gout Drugs Might Increase Patients at Target Urate Level New options in late stages of clinical testing for refractory gout promise to increase the chances of reaching the guideline uric acid target with relatively modest risks for adverse events
Your Gout Friend Your email address is safe - I will never share it with anyone else
Immunosuppressive Therapies in Organ Transplantation - Page 4 The effects of AZA and its active metabolite, 6-MP, may not be observed until several days after initiation of therapy and the drug may have a residual effect for several days after cessation of
Febuxostat for Treatment of Chronic Gout - Page 11 - Medscape Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid
Allopurinol: Extra Caution Urged in High-Risk Groups - Medscape The risk for severe cutaneous adverse reactions to allopurinol was much higher among those who were black, Asian, Native Hawaiian Pacific Islander, women, older, or receiving higher starting doses
FDA Warns of Higher Risk for Death With Gout Drug Febuxostat Febuxostat should be reserved for patients with gout-related hyperuricemia for whom allopurinol has failed or who do not tolerate allopurinol, owing to an increased risk for death, the FDA says